---
schema_version: "secwatch.filing_event.v1"
accession: "0001023024-25-000021"
form_type: "8-K"
ticker: "ANIP"
cik: "0001023024"
company_name: "ANI PHARMACEUTICALS INC"
filed_at: "2025-03-14T23:59:59+00:00"
generated_at: "2026-05-24T17:38:16.789077+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ANI Pharmaceuticals receives FDA approval to expand ILUVIEN label for chronic non-infectious uveitis

## Summary
- FDA approved ILUVIEN for chronic non-infectious uveitis affecting posterior segment (NIU-PS), expanding beyond DME.
- ANI plans to market ILUVIEN under the combined label in the U.S. later this year.
- Extended supply agreement with Siegfried through 2029; equipment upgrade and capacity expansion planned.
- ILUVIEN is already approved for both DME and NIU-PS in 17 European countries.

## SEC filing metadata
- accession: 0001023024-25-000021
- form_type: 8-K
- ticker: ANIP
- cik: 0001023024
- company_name: ANI PHARMACEUTICALS INC
- filed_at: 2025-03-14T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1023024/000102302425000021/0001023024-25-000021-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1023024/000102302425000021/ani-20250314.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001023024-25-000021
- JSON: https://secwatch.observer/filing/0001023024-25-000021.json
- Plain text: https://secwatch.observer/filing/0001023024-25-000021.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.